研究单位：[1]Chinese SLE Treatment And Research Group[2]Peking Union Medical College Hospital[3]the Affiliated Hospital to Bangbu Medical University,Bangbu, Anhui, China, 233000[4]Hebei Provincial Hospital,Shijiazhuang, Hebei, China, 050051[5]the First Affiliated Hospital of Xiangya Medical University,Changsha, Hunan, China, 410000[6]the Affiliated Hospital of Inner Mongolia Medical University,Huhehaote, Inner Mongolia, China, 010050[7]Sino-Japanese Friendship Hospital of Jilin University,Changchun, Jilin, China, 410008[8]the Affiliated Hospital of Xian Communication Hospital,Xian, Shanxi, China, 710000[9]Xijing Hospital,Xian, Shanxi, China, 710032[10]Xinjiang Provincial Hospital,Urumqi, Xinjiang, China, 830001[11]the Affiliated Hospital of Kunming Medical University,Kunming, Yunnan, China, 650032[12]Beijng Hospital,Beijing, China, 100006[13]Beijing Chaoyang Hospital,Beijing, China, 100020[14]China-Japan Friendship Hospital,Beijing, China, 100029[15]Peking Union Medical College Hospital,Beijing, China, 100032[16]Beijing Xuanwu Hospital,Beijing, China, 100053[17]General Hospital of Tianjing Medical University,Tianjin, China, 300052
Treating severe thrombocytopenia is a challenge in the management of systemic lupus erythematosus. Although rheumatologists have followed some rules in real practice,there is very few evidence to support the current treatment algorithm. The purpose of this study is to compare the complete remission rate and partial remission rate of cyclophosphamide and hydroxychloroquine for treating severe thrombocytopenia in Chinese SLE patients.
